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ABSTRACT
Background: Coronary restenosis is a poorly understood phe-
nomenon that remains a challenge even in the drug-eluting 
stent era. This study aimed to identify genes involved in the 
synthesis of structural and functional proteins in smooth 
muscle cells with increased expression in human athero-
matous plaques associated with neointimal hyperplasia after 
bare-metal stent implantation. Methods: Atheromatous plaques 
were obtained by directional atherectomy prior to stenting. A 
gene expression analysis was performed using the Affymetrix 
GeneChip system. The patients were subjected to intravascu-
lar ultrasound six months after the procedure for an in-stent 
volumetric analysis. The correlation between gene expression 
in atheromatous plaques and the percentage of in-stent intimal 
hyperplasia was evaluated. Results: Most patients were male 
(85.7%) with a mean age of 60.2  ±  11.4 years; 35.7% were 
diabetic, and the percentage of in-stent intimal hyperplasia 
was 29.9  ±  18.7%. There was no change in the percentage 
of in-stent intimal hyperplasia in patients with or without 
diabetes (29.5% vs. 30.7%; P = 0.89). There was no correla-
tion between the stent length and the percentage of in-stent 
intimal hyperplasia (r = −0.26; P = 0.26), or between the stent 
diameter and the percentage of in-stent intimal hyperplasia 
(r  =  0.14; P  =  0.56). Eight genes related to smooth muscle 
cell structural and functional protein synthesis had a positive 
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RESUMO
Identificação de Genes Envolvidos na Síntese 
de Proteínas de Células Musculares Lisas com  
Expressão Aumentada em Placas Ateromatosas 
Associados a Hiperplasia Neointimal após Implante  
de Stents Não Farmacológicos: Estudo GENESIS-R
Introdução: A reestenose coronária é um fenômeno pouco com-
preendido e que permanece como um desafio mesmo na era dos 
stents farmacológicos. Este estudo tem como objetivo identificar 
genes envolvidos na síntese de proteínas estruturais e funcionais 
de células musculares lisas com expressão aumentada em placas 
ateromatosas de humanos associados a hiperplasia neointimal 
após o implante de stents não farmacológicos. Métodos: Placas 
ateromatosas foram obtidas mediante aterectomia direcionada, 
previamente ao implante do stent. A análise da expressão dos 
genes foi realizada utilizando-se o sistema Affymetrix GeneChip. 
Os pacientes foram submetidos a ultrassom intracoronário 
6 meses após o procedimento para análise volumétrica intrastent. 
Foi avaliada a correlação entre a expressão gênica de placas 
ateromatosas e o porcentual de hiperplasia intimal intrastent. 
Resultados: A maioria dos pacientes era do sexo masculino 
(85,7%), com 60,2 ± 11,4 anos de idade, 35,7% eram diabé-
ticos e o porcentual de hiperplasia intimal intrastent foi de 
29,9 ± 18,7%. Não houve variação do porcentual de hiperpla-
sia intimal intrastent entre os pacientes com ou sem diabetes 
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correlation with the percentage of in-stent intimal hyperplasia. 
Conclusions: De novo coronary lesions exhibited an increased 
expression of genes related to the synthesis of structural and 
functional proteins in smooth muscle cells and were associa-
ted with future significant in-stent neointimal hyperplasia, thus 
emerging as novel therapeutic targets.
 
 
 
 
 
DESCRIPTORS: Stents. Drug-eluting stents. Coronary restenosis. 
Gene expression. Atherectomy. Coronary.
(29,5% vs. 30,7%; P = 0,89). Não houve correlação entre a 
extensão do stent e o porcentual de hiperplasia intimal intrastent 
(r = –0,26; P = 0,26) ou entre o diâmetro do stent e o porcentual 
de hiperplasia intimal intrastent (r = 0,14; P = 0,56). Oito genes 
envolvidos na síntese de proteínas estruturais e funcionais de 
células musculares lisas apresentaram correlação positiva com 
o porcentual de hiperplasia intimal intrastent. Conclusões: As 
lesões coronárias de novo apresentam expressão aumentada 
de genes relacionados com a síntese de proteínas estruturais 
e funcionais de células musculares lisas associados a futura 
hiperplasia neointimal intrastent significativa, surgindo como 
novos alvos terapêuticos.
DESCRITORES: Stents. Stents farmacológicos. Reestenose 
coronária. Expressão gênica. Aterectomia coronária.
N eointimal proliferation is the main physiopatho-logical mechanism of intrastent restenosis that, even after the introduction of drug-eluting stents, 
still remains a problem. Neointimal prolife ration is 
responsible for most adverse cardiovascular events in 
patients undergoing percutaneous coronary interven-
tion.1–3 It is a cicatricial process resulting from the 
trauma caused by the stent implantation on the ves-
sel wall. The vessel wall smooth muscle cells that are 
involved in restenosis migrate from the tunica media 
to the intimal layer of the coronary artery, proliferate, 
and cause the abundant production of the extracellular 
matrix.1–4 Several studies with coronary angiography 
and intracoronary ultrasound have demonstrated that 
the atheromatous plaque has basal characteristics 
predictive of restenosis.5–7 However, studies designed 
to identify genetic predictors of restenosis evaluated 
only neointimal tissue.8,9 Thus, the currently available 
genetic data on atheromatous plaques in humans are 
limited and virtually insignificant when its association 
with restenosis is assessed.
The aim of this study was to evaluate the associa-
tion between the expression of genes involved in the 
synthesis of smooth muscle cell structural and functional 
proteins in atheromatous plaques (de novo lesion) in 
humans and neointimal proliferation after bare-metal 
stent implantation.
METHODS
Sample
Overall, 40 patients with coronary artery disease 
and an indication of percutaneous coronary intervention 
underwent guided atherectomy followed by bare-metal 
stenting. The exclusion criteria were saphenous vein 
bypass lesion, ostial lesion of the right coronary artery, 
intrastent restenosis, and history of heart transplantation 
or dilated or restrictive cardiomyopathy. The study was 
approved by the Ethics and Research Committee of the 
Hospital de Clínicas de Porto Alegre (Porto Alegre, RS, 
Brazil), and all patients were included after signing an 
informed consent.
Procedure
The patients were submitted to intracoronary ul-
trasound assessment prior to percutaneous coronary 
intervention to obtain data related to the atheromatous 
plaque and vessel size. Subsequently, the atherectomy 
was performed with the guidance of a Flexicut catheter 
(Guidant Corp., Temecula, CA, USA) to remove the 
atheromatous plaque. Guided atherectomy was per-
formed using an 8-F guide catheter; the balloon was 
inflated under low pressure (approximately 0.5  atm), 
and the device was driven at a speed of 2,000  rpm, 
aiming to excise the atheromatous plaque.9 The proce-
dure was successfully and uneventfully performed in 
40 patients, yielding a satisfactory amount of material 
(atheromatous plaque). Finally, the patients underwent 
bare-metal stenting followed by an assessment using 
intracoronary ultrasound to ensure proper stent expan-
sion and apposition. When necessary, post-dilation 
was performed, followed by a new assessment using 
intracoronary ultrasound.
Quantitative analyses
Quantitative coronary analysis and ultrasound 
assessment were performed after administering bolus 
intracoronary nitrate during percutaneous coronary 
intervention and angiographic and ultrasound restudies. 
The intracoronary ultrasound images were acquired 
using a motorised traction device at 0.5  mm/s. A 
quantitative angiographic analysis was performed by 
independent researchers at the Hospital de Clínicas de 
Porto Alegre, whereas ultrasound analyses were per-
formed by independent researchers at the UH Hospitals 
(Cleveland, OH, USA). Stent restenosis was defined 
as stenosis with an intrastent diameter ≥  50% upon 
angiographic restudy. The minimum luminal diameter 
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and percentage of intrastent stenosis were measured in 
each stent. Late intrastent luminal loss was calculated as 
the post-implantation minimum luminal stent diameter 
minus the minimum luminal diameter upon angiographic 
restudy. The intimal hyperplasia volume was calculated 
as the stent volume minus the luminal volume. The 
percentage of intimal hyperplasia was defined as the 
intimal hyperplasia volume divided by the stent volume. 
The percentage of intimal hyperplasia was determined 
to be correlated with the gene expression parameter, 
as it is more representative of neointimal proliferation 
and allows for the equalisation of different diameters 
and extensions of the analysed stents.
Gene expression analysis
The fragments of atheromatous plaque (de novo lesion) 
were placed in Eppendorf tubes containing RNA Stat 60, 
stored in liquid nitrogen and subsequently sent to the 
Millennium Pharmaceuticals Laboratory (Cambridge, MA, 
USA) for gene expression analysis. The ribonucleic acid 
(RNA) was isolated from atheromatous plaque samples 
through homogenisation in the PowerGen equipment 
model 125 (Thermo Fisher Scientific – Waltham, MA, 
USA), followed by extraction with chloroform, precipita-
tion with isopropanol, washing with 75% ethanol and, 
finally, dissolving in ribonuclease-free water. The RNA 
concentration was measured using a NanoDrop spec-
trophotometer (Thermo Fisher Scientific), and the quality 
and purity of the RNA were assessed using a RNA 6000 
peak or nano assay (Agilent 2100 Bioanalyzer, Agilent 
Technologies – Santa Clara, CA, USA). Finally, the RNA 
sample was amplified using a specific protocol, and the 
gene expression of each sample was measured using the 
chips and the Affymetrix GeneChip microarray system 
(Affymetrix – Santa Clara, CA, USA).
Statistical analysis
Categorical variables were expressed as absolute 
numbers and percentages and continuous variables as 
the mean ± standard deviation. Student’s t-test was used 
to assess the relationship between diabetes mellitus and 
the percentage of intimal hyperplasia. Pearson’s correla-
tion was used to evaluate the relationship between the 
stent length and diameter and the percentage of intimal 
hyperplasia, as well as the relationship between gene 
expression and the amount of neointimal hyperplasia 
expressed as the percentage of intimal hyperplasia. 
A total of 29 atheromatous plaques were assessed as 
required for rho (r) ≥  0.5, a statistical power of 80%, 
and an alpha error (P) < 0.05. Nineteen atheromatous 
plaques were required for r  ≥  0.6, a statistical power 
of 80%, and P  <  0.05 (two-tailed).10
RESULTS
Overall, 40 patients underwent guided atherectomy 
followed by bare-metal stenting, and 28 of them provided 
atheromatous plaque samples with an RNA amount that 
was suitable for analysis (one atheromatous plaque/
patient). Clinical and procedural characteristics demon-
strated a mean age of 60.2 ± 11.4 years and diabetes 
mellitus in 35.7% of the analysed patients (Table 1). 
The volume of intimal hyperplasia in the restudy was 
52.8  ±  28.2  mm3, whereas the percentage of intimal 
hyperplasia was 29.9  ±  18.7% (Table 2).
There was no significant variation in the percentage 
of neointimal hyperplasia in the restudy between patients 
with or without diabetes mellitus (29.5% in diabetics 
and 30.7% in non-diabetics, P = 0.89). Moreover, there 
was no significant correlation between the stent length 
and the percentage of intimal hyperplasia (r  =  −0.26; 
P = 0.26), or between the stent diameter and the per-
centage of intimal hyperplasia (r  =  0.14; P  =  0.56).
A gene expression analysis indicated a positive 
correlation between eight genes involved in the smooth 
muscle cell structural and functional protein synthesis 
and the percentage of intimal hyperplasia (Table 3).
TABLE 1 
Clinical and Angiographic Characteristics
n = 28
Age, years 
Male gender, n (%) 
Diabetes mellitus, n (%) 
Systemic arterial hypertension, n (%) 
Dyslipidemia, n (%) 
Smoking, n (%) 
Acute coronary syndrome, n (%) 
Coronary arteries, n (%)
 Left anterior descending
 Circumflex 
 Right coronary
pre-intervention angiographic findings 
 Reference vessel diameter, mm 
 Lesion length, mm 
 Stenosis, % 
 Minimal luminal diameter, mm 
Post-intervention angiographic 
findings
 Intrastent minimal luminal  
 diameter, mm 
 Residual stenosis, mm 
Procedure details
 Stent length, mm 
 Stent /coronary diameter ratio
60.2 ± 11.4
24 (85.7)
10 (35.7)
18 (64.3)
17 (60.7)
15 (53.6)
22 (78.6)
18 (64.3)
4 (14.3)
6 (21.4)
3.49 ± 0.22
16.3 ± 4.8
76.2 ± 10.1
0.83 ± 0.36
 
3.33 ± 0.29 
6 ± 4.4
20.2 ± 4.6
1.01 ± 0.02
n = number of patients.
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DISCUSSION
Restenosis is an important limitation of percutaneous 
coronary intervention. Although drug-eluting stents have 
reduced restenosis rates when compared with bare-metal 
stents, intrastent restenosis still occurs in 7% to 8% of 
patients, particularly in high-risk situations such as long 
lesions, small-calibre vessels, and patients with diabetes 
mellitus or chronic renal failure.2,3 For this reason, and 
due to other problems such as intrastent thrombosis and 
the need for prolonged dual antiplatelet therapy, there 
is continued interest in understanding the mechanisms 
involved in the physiopathology of restenosis.
After the mechanical trauma caused by stent im-
plantation, a series of events occurs that determines 
the proliferation of smooth muscle cells and abundant 
extracellular matrix synthesis, which are the main 
neointimal components.1,10–13 The results of this study 
indicate that the atheromatous plaques treated by bare-
metal stenting and that develop significant neointimal 
hyperplasia exhibit an increased expression of genes 
related to smooth muscle cell structural and functional 
protein synthesis prior to stent implantation. Consequently, 
the results of this study suggest that the atheromatous 
plaque has an inherent predisposition to significant 
neointimal formation that precedes stent implantation. 
These data are being described for the first time, as 
there are no reports of similar studies in the literature. 
The identification of the enhanced expression of 
genes related to smooth muscle cell structural and 
functional protein synthesis, which constitutes the 
cellular basis of restenosis, in atheromatous plaques 
prone to intrastent restenosis opens a new path for the 
development of cell antiproliferative drugs that can act 
on the newly formed protein. In the present results, a 
TABLE 2 
Ultrasonographic and Angiographic Restudy
n = 28
Late loss, mm 1.07 ± 0.75
Late loss index 0.43 ± 0.24
Stent volume, mm³ 198 ± 56.3
Lumen volume, mm³ 145.3 ± 51.8
Neointimal volume, mm³ 52.8 ± 28.2
Percentage of intimal hyperplasia, % 29.9 ± 18.7
n = number of patients.
TABLE 3 
Correlation between Genes Involved in Smooth Muscle Cell Structural and Functional  
Protein Synthesis and Percentage of Intimal Hyperplasia
P Correlation
Gene
Description Function
0.0000 0.78 CNN1 
(Calponin 1, smooth muscle)
Smooth muscle structural protein  
0.0012 0.67 MYH11 isoform 1 
(Myosin heavy chain 11 isoform, smooth muscle)
Smooth muscle structural protein 
0.0030 0.63 MYH11 isoform 2 
(Myosin, heavy chain 11, smooth muscle)
Smooth muscle structural protein 
0.0046 0.61 LMOD1  
(Leiomodin 1, smooth muscle)
Smooth muscle structural protein 
0.0148 0.54 MYL9  
(Myosin light chain 9, regulatory)
Smooth muscle structural protein 
0.0152 0.53 TPM1  
(Tropomyosin alpha-1)
Smooth muscle cell contractility 
0.0157 0.53 MYLK  
(Myosin light chain kinase)
Smooth muscle cell contractility 
0.0258 0.51 SMTN  
(Smoothelin)
Smooth muscle structural protein 
0.0232 0.50 CALD1  
(Caldesmon 1)
Smooth muscle activity regulation  
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microarray analysis has identified two mRNA isoforms 
of myosin heavy chain 11, which supports the role 
of an increased production of proteins related to the 
structural development of smooth muscle cells. Isoforms 
are mRNAs with distinct nucleotide sequences that are 
formed by alternative splicing, and are capable of pro-
ducing the same protein. Each gene produces multiple 
mRNAs and isoforms.14 The identification of mRNA 
isoforms in specific genes with increased expression 
emphasises the discovery of non-random findings, and 
further supports the obtained results.
Cells are capable of following alternative metabolic 
pathways that allow cell cycle progression, which ex-
plains the significant failure rate of drug-eluting stents 
that deliver commercially available cell antiproliferative 
drugs to prevent restenosis. Another important aspect 
to be discussed is the delayed stent endothelialisation, 
requiring prolonged use of dual antiplatelet therapy due 
to the risk of stent thrombosis. This therapy is a serious 
limitation for patients who need to undergo planned 
surgeries and for high-risk patients who require emer-
gency surgery, in addition to the increased risk of minor 
and/or major bleeding.15–19 Therefore, gene therapy 
aimed at inhibiting smooth muscle cell structural and 
functional protein synthesis constitutes a new paradigm 
for the production of DES that can act by selectively 
inhibiting smooth muscle cell proliferation without 
affecting the physiological production of endothelial 
cells and, consequently, stent endothelialisation in a 
short-time interval, as it occurs with bare-metal stents. 
The influence of clinical factors, such as diabetes 
mellitus, and of angiographic factors, such as lesion 
length and vessel size, on the intrastent restenosis 
of bare-metal stents is well established.2,20–23 Clinical 
studies have demonstrated that diabetes is a strong 
independent predictor of stent restenosis, and that 
long lesions and small-calibre vessel lesions are also 
independent predictors of intrastent restenosis. There-
fore, these well-known clinical and angiographic fac-
tor predictors of intrastent restenosis were assessed to 
analyse their influence on the present sample, aiming 
to identify statistically possible confounding factors. 
The results indicated no association between diabetes 
mellitus and the intrastent neointimal hyperplasia vol-
ume. Moreover, there was no correlation between the 
stent length, which is directly associated with lesion 
extension, and the neointimal hyperplasia volume; there 
was also no correlation between the stent diameter, 
which is directly associated with the vessel diameter, 
and the neointimal hyperplasia volume. The results of 
this study, therefore, did not suffer from the influence 
of clinical and angiographic factors, and the analysis 
of these results is restricted to cell and genetic factors. 
The analysis of gene expression using mRNA 
microarray technology has become a popular tool to 
simultaneously evaluate the expression of thousands of 
genes and has been widely applied in cardiovascular 
research to detect gene expression patterns under dif-
ferent conditions. There are few studies available in 
the literature that use this technique to assess gene 
expression in atherosclerotic plaques and neointimal 
intrastent in humans. In one study, ten neointimal 
specimens removed by guided atherectomy were 
compared with seven coronary artery samples and 
seven gastrointestinal artery samples.9 The authors 
reported different genes with increased expression in 
the neointima when compared with the aforementioned 
arteries. In another study, Ashley et al.8 compared 
samples of atheromatous plaques with tissue derived 
from intrastent restenosis by histological and gene ex-
pression analysis. Histo logy indicated a higher amount 
of cells and fewer inflammatory infiltrates and lipid 
pools in the restenosis group compared with the ath-
eromatous plaque group. The gene expression analysis 
demonstrated a predominance of cell proliferation and 
the inflammatory/immune response in the restenosis 
group when compared with the atheromatous plaque 
group. The network analysis highlighted two modules 
of gene expression as candidates for restenosis pre-
vention (procollagen type 1a2 and ADAM 17/tumour 
necrosis factor-converting enzyme).8 The results of the 
present study contribute to a better understanding of 
gene expression in restenosis by a different approach, 
that is, by demonstrating the correlation between the 
expression of genes involved in smooth muscle cell 
structural and functional protein synthesis in athero-
matous plaques (de novo lesions) and the amount of 
intrastent neointima. According to the literature review, 
this was the first study to report such a correlation. 
In clinical practice, the restenosis outcome may 
vary in the same patient or in the same coronary artery. 
Therefore, intrastent restenosis appears to be more closely 
related to intrinsic factors of the atheromatous plaque 
than to specific variables of the patient or of the coronary 
artery. Some factors related to the atheromatous plaque, 
such as plaque load, the presence of lipid content and 
positive remo delling, have been associated with resteno-
sis.5–7 Consistent with these observations, the results of 
this study support the concept of local predisposition for 
the development of intrastent restenosis by the increased 
expression of genes involved in smooth muscle cell struc-
tural and functional protein synthesis, which most likely 
act by exerting a prominent role in the restenosis process. 
Study limitations
Some limitations should be considered in the present 
study. mRNA extraction and measurement from each 
atheromatous plaque constitute very important and 
diffe rential factors in this study; however, the minimum 
cell number that is necessary for mRNA extraction 
and analysis is not obtained, as atheromatous plaques 
contain large amounts of cholesterol esters and a 
small number of cells. Another limitation is the need 
for validation of the results by direct measurement of 
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protein expression in the atheromatous plaque by a 
Western blot analysis, which was not performed due 
to the small number of cells in the samples obtained 
by guided atherectomy.
The aforementioned are essentially technical limi-
tations of the method (gene expression analysis) and 
the object of study (fragments of atheromatous plaque). 
Therefore, these limitations do not compromise the 
study. The objective of the study was not to definitively 
clarify the physiopathological mechanisms involved in 
restenosis but to identify new factors and help further 
the understanding of the complex process of restenosis, 
seeking safer and more effective solutions.
CONCLUSIONS
De novo coronary lesions exhibit an increased 
expression of genes related to smooth muscle cell 
structural and functional protein synthesis associated 
with future significant intrastent neointimal hyperplasia, 
thus emerging as new therapeutic targets.
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